Previous Close | 2.2350 |
Open | 2.2800 |
Bid | 2.2100 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 2.2800 - 2.4400 |
52 Week Range | 0.6300 - 2.8000 |
Volume | |
Avg. Volume | 2,494 |
Market Cap | 163.526M |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and a
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart FailureARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024Toronto, Ont
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisExceeded 50% enrollment in the Phase II ARCHER trial evaluating CardiolRx™in patients with acute myocarditis; study expected to reach full enrollment during Q3 2024Data presented at the HFSA Annual Scientific S